The anti-obesity drug market will be worth $130 billion by 2030, Goldman Sachs said.New products such as Eli Lilly's Zepbound ...

Semaglutide, the active ingredient in popular diabetes and obesity drugs Ozempic and Wegovy, can also tweak people’s taste ...

Semaglutide medications including Ozempic and Wegovy have been shown to reduce kidney failure risk and the risk of death ...

Novo Nordisk said on Thursday it had sued nine more medical spas, wellness clinics and pharmacies in the U.S. for selling ...

Blockbuster weight-loss drug Wegovy could bankrupt the U.S. health care system unless the price drops, according to a staff ...

As Novo Nordisk and Eli Lilly struggle to keep up with soaring demand for their popular diabetes and weight loss drugs, ...

In a new study, researchers found that semaglutide helps improve taste sensitivity in women with obesity. Participants also ...

Novo Nordisk A/S said it retains about 60% of the list price of Ozempic and Wegovy in the US after rebates and fees paid to ...

GLP-1 drugs like Ozempic and Wegovy may affect your sense of taste and the way your brain responds to sweet foods.

A new study found that Wegovy was linked to a 50% and 56% lower risk of incidence and recurrence of alcohol use disorder over ...

In a letter to Bernie Sanders, Novo Nordisk said it only retains 60% of the list price of either Ozempic or Wegovy ...

Novo Nordisk said it retains about 60% of the list price of its popular diabetes and obesity drugs - Ozempic and Wegovy - ...